ESMO 2017 Congress Report


ESMO 2017 single articles:
• Immunotherapy: once more at the cutting edge of progress
Immunostimulation as a promising approach in SCLC
Randomised findings on CT-based follow-up after resection of early NSCLC
EGFR-mutant lung cancer: sequencing as a major topic in light of new data
Interview: Survival is the result of multiple treatment lines
Reaching unprecedented outcome dimensions in malignant mesothelioma
Characteristics and outcomes for SCLC arising from transformation
ALK-positive NSCLC: updates on crizotinib and alectinib
Rare driver mutations: BRAF- and HER2-mutant NSCLC

Full Report (English)